[1. E. David McIntosh. (2009) - Glycylcyclines: Current Research Directions - STEP Progress in Infection (section 5). Athens, Greece: Wyeth]Search in Google Scholar
[2. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E.( 2005). for the Tigecycline 300 and 305 cSSSI Study Groups - The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: results of 2 double-blind phase 3 comparison studies with vancomycinaztreonam - Clinical Infectious Diseases; 41 Suppl 5 (S341-S353). Oxford University Press.10.1086/43167516080072]Search in Google Scholar
[3. Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ. (2006). - Tigecycline: a novel glycylcycline antibiotic - Expert Rev Anti Infective Therapy 4: (pp.9-25). London: Expert Reviews Ltd.]Search in Google Scholar
[4. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. (2005). for the Tigecycline 301 and 306 Study Groups - The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data.Clinical Infectious Diseases; 41 suppl 5 (S354-S367). ). Oxford University Press.10.1086/43167616080073]Search in Google Scholar
[5. Rita Piscopo, Giovanni Penco, Marcello Feasi, Emanuele Pontali, Nicoletta Bobbio, Giovanni Cassola. (2009). STEP Progress in Infection( section 8). Athens, Greece: Wyeth.]Search in Google Scholar
